The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses

Introduction: TT-01025-CL is an oral, irreversible small molecule that potently inhibits vascular adhesion protein-1 (VAP-1) for the treatment of inflammation associated with non-alcoholic steatohepatitis (NASH). The objectives of this study were to evaluate the safety/tolerability, pharmacokinetics...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuanxun Yang (Author), Lei Yu (Author), Zejuan Sheng (Author), Hui Lin (Author), Zuyi Weng (Author), Wei Song (Author), Bei Cao (Author), Yu Zhao (Author), Yingsheng Gao (Author), Shumao Ni (Author), Huimin Wang (Author), Tingting Ma (Author), Lei Huang (Author), Caixia Sun (Author), Juan Li (Author)
Format: Book
Published: Frontiers Media S.A., 2024-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available